Exact Mass: 519.2581
Exact Mass Matches: 519.2581
Found 248 metabolites which its exact mass value is equals to given mass value 519.2581
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ala Phe Pro Trp
Ala Phe Trp Pro
Ala His His Arg
Ala His Arg His
Ala Ile Met Trp
Ala Ile Trp Met
Ala Leu Met Trp
Ala Leu Trp Met
Ala Met Ile Trp
Ala Met Leu Trp
Ala Met Trp Ile
Ala Met Trp Leu
Ala Pro Phe Trp
Ala Pro Trp Phe
Ala Arg His His
Ala Trp Phe Pro
Ala Trp Ile Met
Ala Trp Leu Met
Ala Trp Met Ile
Ala Trp Met Leu
Ala Trp Pro Phe
Cys Ile Val Trp
Cys Ile Trp Val
Cys Lys Asn Arg
Cys Lys Arg Asn
Cys Leu Val Trp
Cys Leu Trp Val
Cys Asn Lys Arg
Cys Asn Arg Lys
Cys Arg Lys Asn
Cys Arg Asn Lys
Cys Val Ile Trp
Cys Val Leu Trp
Cys Val Trp Ile
Cys Val Trp Leu
Cys Trp Ile Val
Cys Trp Leu Val
Cys Trp Val Ile
Cys Trp Val Leu
Phe Ala Pro Trp
Phe Ala Trp Pro
Phe Pro Ala Trp
Phe Pro Trp Ala
Phe Trp Ala Pro
Phe Trp Pro Ala
His Ala His Arg
His Ala Arg His
His His Ala Arg
His His Ile Asn
His His Leu Asn
His His Asn Ile
His His Asn Leu
His His Gln Val
His His Arg Ala
His His Val Gln
His Ile His Asn
His Ile Asn His
His Leu His Asn
His Leu Asn His
His Asn His Ile
His Asn His Leu
His Asn Ile His
His Asn Leu His
His Gln His Val
His Gln Val His
His Arg Ala His
His Arg His Ala
His Val His Gln
His Val Gln His
Ile Ala Met Trp
Ile Ala Trp Met
Ile Cys Val Trp
Ile Cys Trp Val
Ile His His Asn
Ile His Asn His
Ile Met Ala Trp
Ile Met Trp Ala
Ile Asn His His
Ile Val Cys Trp
Ile Val Trp Cys
Ile Trp Ala Met
Ile Trp Cys Val
Ile Trp Met Ala
Ile Trp Val Cys
Lys Cys Asn Arg
Lys Cys Arg Asn
Lys Asn Cys Arg
Lys Asn Arg Cys
Lys Arg Cys Asn
Lys Arg Asn Cys
Leu Ala Met Trp
Leu Ala Trp Met
Leu Cys Val Trp
Leu Cys Trp Val
Leu His His Asn
Leu His Asn His
Leu Met Ala Trp
Leu Met Trp Ala
Leu Asn His His
Leu Val Cys Trp
Leu Val Trp Cys
Leu Trp Ala Met
Leu Trp Cys Val
Leu Trp Met Ala
Leu Trp Val Cys
Met Ala Ile Trp
Met Ala Leu Trp
Met Ala Trp Ile
Met Ala Trp Leu
Met Ile Ala Trp
Met Ile Trp Ala
Met Leu Ala Trp
Met Leu Trp Ala
Met Trp Ala Ile
Met Trp Ala Leu
Met Trp Ile Ala
Met Trp Leu Ala
Asn Cys Lys Arg
Asn Cys Arg Lys
Asn His His Ile
Asn His His Leu
Asn His Ile His
Asn His Leu His
Asn Ile His His
Asn Lys Cys Arg
Asn Lys Arg Cys
Asn Leu His His
Asn Arg Cys Lys
Asn Arg Lys Cys
Pro Ala Phe Trp
Pro Ala Trp Phe
Pro Phe Ala Trp
Pro Phe Trp Ala
Pro Trp Ala Phe
Pro Trp Phe Ala
Gln His His Val
Gln His Val His
Gln Val His His
Arg Ala His His
Arg Cys Lys Asn
Arg Cys Asn Lys
Arg His Ala His
Arg His His Ala
Arg Lys Cys Asn
Arg Lys Asn Cys
Arg Asn Cys Lys
Arg Asn Lys Cys
Val Cys Ile Trp
Val Cys Leu Trp
Val Cys Trp Ile
Val Cys Trp Leu
Val His His Gln
Val His Gln His
Val Ile Cys Trp
Val Ile Trp Cys
Val Leu Cys Trp
Val Leu Trp Cys
Val Gln His His
Val Trp Cys Ile
Val Trp Cys Leu
Val Trp Ile Cys
Val Trp Leu Cys
Trp Ala Phe Pro
Trp Ala Ile Met
Trp Ala Leu Met
Trp Ala Met Ile
Trp Ala Met Leu
Trp Ala Pro Phe
Trp Cys Ile Val
Trp Cys Leu Val
Trp Cys Val Ile
Trp Cys Val Leu
Trp Phe Ala Pro
Trp Phe Pro Ala
Trp Ile Ala Met
Trp Ile Cys Val
Trp Ile Met Ala
Trp Ile Val Cys
Trp Leu Ala Met
Trp Leu Cys Val
Trp Leu Met Ala
Trp Leu Val Cys
Trp Met Ala Ile
Trp Met Ala Leu
Trp Met Ile Ala
Trp Met Leu Ala
Trp Pro Ala Phe
Trp Pro Phe Ala
Trp Val Cys Ile
Trp Val Cys Leu
Trp Val Ile Cys
Trp Val Leu Cys
WYE-125132(WYE-132)
WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2. WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.
1-palmitoyl-sn-glycero-3-phospho-l-serine sodium salt
(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-({(2R)-2-azaniumyl-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-14-hydroxydocosa-4,7,9,11,16,19-hexaenoate
N-[(4R,7R,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4S,7R,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4S,7S,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7S,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4S,7S,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4R,7S,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7R,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7R,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
(4Z,7Z,16S,17R,19Z)-16-({(2R)-2-azaniumyl-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-17-hydroxydocosa-4,7,10,12,14,19-hexaenoate
(3S)-1-[2-[2,2,2-tris(4-methoxyphenyl)ethoxy]ethyl]-3-piperidinecarboxylic acid
2-amino-3-[hydroxy-[2-hydroxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(13R)-glycinylcystein-S-yl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate(1-)
A docosanoid anion obtained by deprotonation of the two carboxy groups and protonation of the glutamyl alpha-amino group of (13R)-S-cysteinylglycinyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid; major species at pH 7.3.
16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoate(1-)
A docosanoid anion obtained by deprotonation of the two carboxy groups and protonation of the alpha-amino group of 16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid; major species at pH 7.3.
KT185
KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells[1].